期刊论文详细信息
Brazilian Journal of Medical and Biological Research
Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study
A.c. Barreto2  N.y. Maeda1  R.p.s. Soares1  C. Cícero2  A.a. Lopes2 
[1] ,Universidade de São Paulo Instituto do Coração Departamento de Cardiologia Pediátrica e Cardiopatias Congênitas do Adulto
关键词: Pulmonary hypertension;    Statins;    Endothelial dysfunction;    P-selectin;    Tissue-plasminogen activator and inhibitor;    von Willebrand factor;   
DOI  :  10.1590/S0100-879X2008000800003
来源: SciELO
PDF
【 摘 要 】

We investigated whether chronic rosuvastatin administration could improve the abnormalities of the circulating levels of vascular dysfunction markers in pulmonary arterial hypertension (PAH). Sixty patients, aged 13 to 60 years, with idiopathic (N = 14) or congenital heart disease-associated PAH (N = 46) were equally but randomly assigned to rosuvastatin treatment (10 mg a day, orally) or placebo for 6 months in a blind fashion. Plasma levels of P-selectin, tissue-plasminogen activator and its inhibitor as well as von Willebrand factor antigen were measured by enzyme-linked immunoassay before and after 1, 3, and 6 months of treatment. Baseline levels of biomarkers were elevated (68, 16, 45 and 46% increase relative to controls, for P-selectin, von Willebrand factor antigen, tissue-plasminogen activator and its inhibitor, respectively; P < 0.001). P-selectin values at baseline, 1, 3, and 6 months were 39.9 ± 18.5, 37.6 ± 14.6, 34.8 ± 14.6, and 35.4 ± 13.9 ng/mL, respectively, for the rosuvastatin group and 45.7 ± 26.8, 48.0 ± 26.9, 48.1 ± 25.7, and 45.7 ± 25.6 ng/mL for the placebo group. The P-selectin level was lower in the rosuvastatin group compared with placebo throughout treatment (P = 0.037, general linear model). A trend was observed towards a decrease in tissue-plasminogen activator in the statin group (16% reduction, P = 0.094), with no significant changes in the other markers. Since P-selectin is crucial in inflammation and thrombosis, its reduction by rosuvastatin is potentially relevant in the pathophysiological scenario of PAH.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License

【 预 览 】
附件列表
Files Size Format View
RO202103040078200ZK.pdf 553KB PDF download
  文献评价指标  
  下载次数:6次 浏览次数:8次